Comparing chemotherapy options for newly diagnosed AML in young patients
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 months and 22 years old.
- You must have newly diagnosed AML (a blood cancer) without prior treatment except for a few allowed medicines.
- Before joining, you need to have a blood or bone marrow sample tested for FLT3 gene changes.
- If you have a specific FLT3 mutation, you may be eligible for a newer targeted drug (gilteritinib) added to chemotherapy.
- You need to have adequate heart function, not be pregnant or breastfeeding, and agree to use birth control if applicable.
- You must be able to participate in a long-term study with regular follow-ups.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares three different drug combinations for younger adults (18-59) with intermediate-risk AML. You will be assigned to one of three groups: standard chemotherapy (cytarabine + daunorubicin), that same chemotherapy plus venetoclax, or venetoclax combined with azacitidine.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This trial tests a new combination of medications against a standard treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3-ITD mutation. The goal is to find out if the new combination works better and has fewer side effects. If you have this type of AML, you might be able to join and get access to newer drugs.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This study tests whether CPX-351 can work better than standard intensive chemotherapy in adults with newly diagnosed AML that fits specific genetic patterns. It aims to improve how long patients stay in control of the leukemia.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.